BioCardia (BCDA) Stock Price, News & Analysis

Company Overview

BioCardia, Inc. (NASDAQ: BCDA) is a clinical‐stage biotechnology company focused on the development and commercialization of cell‐based therapies for cardiovascular and pulmonary diseases. The company’s proprietary Helix biotherapeutic delivery system is designed to facilitate precise intramyocardial and intravascular delivery of therapeutic cells or biologics. BioCardia’s lead clinical programs include CardiAMP™ for ischemic heart failure, which employs patients’ own bone marrow‐derived cells to promote neovascularization and improve cardiac function, and CardiALLO™, an off‐the‐shelf allogeneic cell therapy in development for similar indications.

Beyond its core cardiovascular pipeline, BioCardia is exploring additional regenerative medicine applications in pulmonary arterial hypertension and chronic obstructive pulmonary disease. The Helix catheter platform supports these efforts by enabling targeted cell administration to affected tissue beds. The company also offers a suite of development services, including cell processing, quality control and regulatory support, aimed at advancing investigator‐sponsored trials and potential strategic partnerships with larger pharmaceutical and medical device companies.

Founded in 2004 and headquartered in Newark, California, BioCardia has conducted clinical studies across multiple centers in the United States and Europe. The company maintains collaborations with leading academic institutions and clinical investigators to evaluate safety and efficacy outcomes. These multi‐center trials are designed to fulfill regulatory requirements for potential marketing approvals in North America, the European Union and other global markets.

Leadership at BioCardia is headed by President and Chief Executive Officer David Mazzo, who brings more than two decades of experience in life sciences, including previous roles at Becton Dickinson and Novartis. The company’s board and management team combine expertise in interventional cardiology, cell therapy manufacturing, and regulatory affairs. BioCardia continues to advance its clinical programs with the goal of offering new therapeutic options for patients with unmet medical needs in cardiovascular and pulmonary disease.

Key Stats

• Today's Range: $2.26 to $2.35
• 50-Day Range: $1.88 to $2.85
• 52-Week Range: $1.63 to $4.66
• Volume: 32,473 shs
• Average Volume: 276,798 shs
• Market Capitalization: $12.90 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $25.00
• Consensus Rating: Strong Buy

BioCardia Stock Analysis - MarketRank™

BioCardia scored higher than 70% of companies evaluated by MarketBeat, and ranked 317th out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Strong Buy

Consensus Rating

BioCardia has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

BioCardia has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for BioCardia are expected to grow in the coming year, from ($3.52) to ($1.22) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of BioCardia is -0.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of BioCardia is -0.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

BioCardia has a P/B Ratio of 13.03. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.54% of the float of BioCardia has been sold short.

Short Interest Ratio / Days to Cover

BioCardia has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in BioCardia has recently increased by 54.07%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BioCardia does not currently pay a dividend.

Dividend Growth

BioCardia does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.54% of the float of BioCardia has been sold short.

Short Interest Ratio / Days to Cover

BioCardia has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in BioCardia has recently increased by 54.07%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.8 / 5
• News Sentiment: N/A

News Sentiment

BioCardia has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.99 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for BioCardia this week, compared to 1 article on an average week.

Search Interest

2 people have searched for BCDA on MarketBeat in the last 30 days.

MarketBeat Follows

2 people have added BioCardia to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, BioCardia insiders have bought more of their company's stock than they have sold. Specifically, they have bought $442,174.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

20.00% of the stock of BioCardia is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 20.57% of the stock of BioCardia is held by institutions.

BCDA Stock Analysis - Frequently Asked Questions

How have BCDA shares performed this year?

BioCardia's stock was trading at $2.18 at the beginning of 2025. Since then, BCDA stock has increased by 7.6% and is now trading at $2.3450.

How were BioCardia's earnings last quarter?

BioCardia, Inc. (NASDAQ:BCDA) posted its quarterly earnings results on Wednesday, May, 14th. The company reported ($0.59) EPS for the quarter, missing the consensus estimate of ($0.39) by $0.20.
Read the conference call transcript.

When did BioCardia's stock split?

BioCardia shares reverse split on the morning of Thursday, May 30th 2024.The 1-15 reverse split was announced on Thursday, May 30th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 30th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

When did BioCardia IPO?

BioCardia (BCDA) raised $51 million in an initial public offering (IPO) on the week of July 20th 2015. The company issued 3,900,000 shares at a price of $12.00-$14.00 per share. Cantor Fitzgerald & Co. acted as the underwriter for the IPO and Roth Capital Partners and Maxim Group were co-managers.

How do I buy shares of BioCardia?

Shares of BCDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of BioCardia own?

Based on aggregate information from My MarketBeat watchlists, some other companies that BioCardia investors own include Invesco QQQ (QQQ), SPDR S&P 500 ETF Trust (SPY), SPDR Dow Jones Industrial Average ETF Trust (DIA), Predictive Oncology (POAI), Abbott Laboratories (ABT), Ford Motor (F) and Wells Fargo & Company (WFC).

Company Calendar

• Last Earnings: 5/14/2025
• Today: 7/15/2025
• Next Earnings (Estimated): 8/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:BCDA
• CIK: 925741
• Web: www.biocardia.com
• Phone: (650) 226-0120
• Fax: 310-861-5299
• Employees: 40
• Year Founded: N/A

Price Target and Rating

• Average Price Target for BioCardia: $25.00
• High Price Target: $25.00
• Low Price Target: $25.00
• Potential Upside/Downside: +973.0%
• Consensus Rating: Strong Buy
• Rating Score (0-4): 3.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.33)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$7.95 million
• Net Margins: N/A
• Pretax Margin: -279,700.00%
• Return on Equity: -30,792.60%
• Return on Assets: -223.06%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.36
• Quick Ratio: 0.36

Sales & Book Value

• Annual Sales: $60 thousand
• Price / Sales: 213.58
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.18 per share
• Price / Book: 12.94

Miscellaneous

• Outstanding Shares: 5,500,000
• Free Float: 4,403,000
• Market Cap: $12.82 million
• Optionable: Optionable
• Beta: 0.81